A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies
← catalyst calendarSponsored by Prelude Therapeutics (industry) · PRLD — their whole pipeline →. With BeiGene.
Phase
Phase 1
Status
Completed
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
86actual
Sites
24
Countries
Australia, Canada, France +7
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-09-12 | actual | When the study began enrolling |
| Primary completion | 2025-06-12 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-01-21 | actual | The whole study's end, after follow-up |
| First posted | 2022-12-27 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-01-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)
- Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
- Mantle Cell Lymphoma (MCL)
- Richter's Syndrome
- T-cell Lymphoma
- Diffuse Large B-cell Lymphoma (DLBCL)
- Marginal Zone Lymphoma
- Myeloid Malignancies
- Acute Myeloid Leukemia (AML)
- Chronic Myelomonocytic Leukemia (CMML)
- Myelodysplastic Syndrome (MDS)
- MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome
Interventions
- Drug: PRT2527
- Drug: Zanubrutinib
- Drug: Venetoclax
Primary outcomes
what the primary-completion date above is the date OFDose limiting toxicity (DLT) of PRT2527
measured Baseline through Day 21, 28, or 35 days.
Safety and tolerability of PRT2527 monotherapy and in combination with zanubrutinib or venetoclax: AEs, CTCAE Assessments
measured Baseline through approximately 2 years
Maximum tolerated dose (MTD)/Recommended phase 2 dose (RP2D) of PRT2527 monotherapy and in combination with zanubrutinib or venetoclax
measured Baseline through approximately 2 years
Permalink · PRLD's whole pipeline · Catalyst calendar · Every registered study · What changed